Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
SAN DIEGO, May 3, 2022 (GLOBE NEWSWIRE) - Travere Therapeutics (NASDAQ: TVTX) announced that CEO Eric Dube, Ph.D., will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:00 p.m. PT. A live webcast of the presentation will be available, along with an archived replay accessible for 30 days post-event.
Travere Therapeutics focuses on developing therapies for patients with rare diseases, emphasizing the need for urgent treatment options and collaboration with the rare disease community.
Travere Therapeutics (NASDAQ: TVTX) plans to release its first quarter 2022 financial results on May 5, 2022, following the U.S. market close. A conference call and webcast to discuss these results and provide a business update is scheduled for 4:30 p.m. ET.
Investors can join the call using the provided dial-in numbers, and a replay will be accessible from 7:30 p.m. ET on May 5 until 7:30 p.m. ET on May 12.
Travere Therapeutics (NASDAQ: TVTX) announced that CFO Laura Clague will retire in August 2022 after seven years, transitioning to an advisory role until 2023. Chris Cline, current SVP of Investor Relations & Corporate Communications, will succeed her, effective the same month. CEO Eric Dube praised Clague's contributions that established a strong financial position for the company. Cline, a finance expert with over 15 years in the industry, is expected to enhance the company’s growth phase and strengthen its commitment to the rare disease community.
Travere Therapeutics (NASDAQ: TVTX) announced on April 10, 2022, that its Compensation Committee granted 13 new employees inducement equity grants. These grants consist of 51,750 restricted stock units (RSUs), which are tied to the company’s 2018 Equity Incentive Plan. The RSUs will vest over four years, with 25% vesting each year, contingent on the employees maintaining their service relationship with the company. This initiative aims to attract talent crucial for advancing Travere's mission in rare disease therapies.
Travere Therapeutics (NASDAQ: TVTX) announced the presentation of data from its ongoing Phase 1/2 COMPOSE Study of pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU), at two significant conferences. The SIMD 43rd Annual Meeting will take place from April 10-13, 2022, in Orlando, FL, while the 2022 GMDI Conference is scheduled for May 4-7, 2022, in Lake Las Vegas, NV. Initial results have shown a 55.1% mean reduction in total homocysteine levels. Current HCU treatments are limited, highlighting the need for innovative therapies like pegtibatinase.
Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.
Travere Therapeutics (NASDAQ: TVTX) announced the submission of a New Drug Application (NDA) for accelerated approval of sparsentan to the FDA for treating IgA nephropathy (IgAN). This marks a significant milestone aimed at addressing the unmet need for effective treatments for this rare kidney disease. The NDA is supported by positive interim results from the pivotal Phase 3 PROTECT Study, which involved 404 patients and showed a 49.8% reduction in proteinuria. The company anticipates updates from the FDA regarding the NDA acceptance by May 2022.
Travere Therapeutics (NASDAQ: TVTX) announced the grant of inducement equity awards totaling 58,000 shares to eight new employees. The grant includes 25,000 stock options and 33,000 restricted stock units (RSUs), aimed to attract talent in accordance with Nasdaq regulations. The stock options have an exercise price of $25.42 and will vest over four years, while the RSUs will also vest in four annual installments. This strategic move underscores Travere’s commitment to building its workforce to advance rare disease therapies.
Travere Therapeutics (Nasdaq: TVTX) announced the pricing of its underwritten offering of $275 million in 2.25% convertible senior notes due 2029. The offering, which is set to close on March 11, 2022, was increased from an initial $250 million. Travere aims to use around $207.1 million of the net proceeds to repurchase outstanding 2025 convertible notes. The net proceeds are estimated at approximately $266.3 million, potentially rising to $306.3 million if the underwriters exercise their over-allotment option. The notes are convertible under specific conditions and may not be redeemed until March 2, 2026.
Travere Therapeutics (Nasdaq: TVTX) announced a proposed offering of $250 million in convertible senior notes due 2029, with a possibility of an additional $37.5 million for over-allotments. The company intends to use a portion of the proceeds to repurchase some of its outstanding 2.50% senior convertible notes due 2025. The notes will be senior unsecured obligations and will accrue interest payable semiannually. The offering has been registered under the Securities Act of 1933, with further details available in the preliminary prospectus filed with the SEC.